Valuation : Rigel Pharmaceuticals, Inc.

Market Cap 887M 765M 721M 657M 1.23B 83.82B 1.24B 8.54B 3.31B 42.85B 3.33B 3.26B 141B P/E 2026 *
15.2x
P/E 2027 * 12.2x
Enterprise Value 887M 765M 721M 657M 1.23B 83.82B 1.24B 8.54B 3.31B 42.85B 3.33B 3.26B 141B EV / Sales 2026 *
2.9x
EV / Sales 2027 * 2.38x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+3.87%
1 week+5.71%
Current month+7.02%
1 month+34.26%
3 months+65.51%
6 months+42.26%
Current year+15.39%
1 week 45.31
Extreme 45.31
49.7
1 month 36.44
Extreme 36.44
49.7
Current year 24.95
Extreme 24.95
49.7
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 Free

Chief Technology Officer

24,400 0.1319%
6/1/26 Exercice

Chief Financial Officer

7,690 0.0416%
6/1/26 Tax

Compliance Officer

-877 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
+4.04%+5.71%+27.21%+318.81% 887M
+0.01%-5.96%+58.36%+108.23% 1,034B
+1.48%+0.76%+55.34%+71.49% 654B
+0.67%-1.53%+24.39%+76.60% 459B
+0.49%-6.58%+34.20%+34.59% 343B
+0.27%+2.32%+29.33%+46.97% 307B
+0.12%-4.01%+1.06%+11.93% 251B
+1.08%+0.14%+53.92%+72.51% 237B
+2.64%-2.00%-17.38%-53.64% 202B
-0.21%+0.56%+32.43%+95.19% 186B
Average +1.10%-2.36%+29.89%+78.27% 367.25B
Weighted average by Cap. +0.71%-3.31%+39.21%+67.37%

Financials

2026 *2027 *
Net sales 306M 264M 248M 226M 423M 28.88B 426M 2.94B 1.14B 14.77B 1.15B 1.12B 48.51B 373M 322M 303M 276M 516M 35.22B 520M 3.59B 1.39B 18.01B 1.4B 1.37B 59.15B
Net income 61.66M 53.19M 50.11M 45.65M 85.33M 5.82B 85.97M 593M 230M 2.98B 232M 226M 9.78B 81.45M 70.26M 66.19M 60.31M 113M 7.69B 114M 784M 304M 3.93B 306M 299M 12.92B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-09-02 US$49.42 +4.04% 184,666
26-09-01 US$47.50 +2.86% 205,505
26-08-31 US$46.18 -0.65% 243,090
26-08-28 US$46.48 -0.81% 246,125
26-08-27 US$46.86 +0.82% 210,027
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
47.50USD
Average target price
63.00USD
Spread / Average Target
+32.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock